Transcriptomic profiling of lineage transformation and actionable therapy opportunities in EGFR-mutant non-small cell lung cancer evolving to small cell lung cancer
The immune landscape of T-SCLC is more immunosuppressed than EGFRm LUAD, yet more immunologically active than that of P-SCLC, and this immune profile provides a rationale for integrating immunotherapy with chemotherapy in T-SCLC.